Related Experiment Video
Updated: Mar 20, 2026
12:54
Operation of a Benchtop Bioreactor
Published on: September 12, 2013
92.6K
30 years hids-Travels between bedside and bench
1Radboud University Medical Center ; Nijmegen, The Netherlands.
Temperature (Austin, Tex.)
|May 27, 2016
Summary
Hyperimmunoglobulin D syndrome (HIDS) research reveals a link between mevalonate kinase gene mutations and elevated IL-1b production. Anakinra offers an effective treatment for this autoinflammatory condition.
Area of Science:
- Immunology
- Genetics
- Biochemistry
Background:
- Hyperimmunoglobulin D syndrome (HIDS) is a periodic fever syndrome.
- Early research focused on understanding the fever and acute phase response in HIDS patients.
Purpose of the Study:
- To investigate the pathogenesis of HIDS.
- To identify the genetic basis of HIDS.
- To explore therapeutic strategies for HIDS.
Main Methods:
- Studied interleukin-1 (IL-1) production by white blood cells.
- Identified mutations in the mevalonate kinase gene.
- Evaluated the efficacy of recombinant interleukin-1 receptor antagonist (anakinra).
Main Results:
- Elevated spontaneous production of IL-1b by white blood cells was observed.
- Mutations in the mevalonate kinase gene were identified as the cause of HIDS.
- Anakinra demonstrated effectiveness in treating the majority of HIDS patients.
Conclusions:
- Over three decades, research has significantly advanced the understanding of HIDS pathogenesis.
- The identification of the mevalonate kinase defect and IL-1b involvement provides crucial insights.
- Anakinra represents a significant therapeutic advancement for HIDS.
